BioVie Inc. (BIVI)
| Market Cap | 10.79M -20.7% |
| Revenue (ttm) | n/a |
| Net Income | -22.12M |
| EPS | -3.05 |
| Shares Out | 7.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,818 |
| Open | 1.390 |
| Previous Close | 1.380 |
| Day's Range | 1.380 - 1.490 |
| 52-Week Range | 0.820 - 3.790 |
| Beta | 0.73 |
| Analysts | Strong Buy |
| Price Target | 5.26 (+267.83%) |
| Est. Earnings | Nov 13, 2026 |
About BIVI
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to mo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for BIVI stock is "Strong Buy." The 12-month stock price target is $5.26, which is an increase of 267.83% from the latest price.
News
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH's RECOVER-TLC Third Annual Workshop
CARSON CITY, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodeg...
BioVie presents results from SUNRISE-PD clinical trial evaluating bezisterim
BioVie (BIVI) announced the presentation of results from the Phase 2 SUNRISE-PD clinical trial evaluating bezisterim in early Parkinson’s patients at the 151st Annual Meeting of the American Neurologi...
BioVie Presents Data on Bezisterim in Parkinson's Disease at the 2026 American Neurological Association Annual Meeting
Parkinson's patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev.
BioVie presents Phase 2 data on bezisterim in Long COVID
BioVie (BIVI) announced the presentation of results from the Phase 2 ADDRESS-LC study evaluating bezisterim in patients with Long COVID at the 151st Annual Meeting of the American Neurological Associa...
BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodeg...
BioVie Proxy statement: Proxy filing
BioVie filed a proxy statement on September 28, 2026, providing details for shareholder voting and corporate governance matters.
BioVie Transcript: Status update
Bezisterim demonstrated statistically significant improvements in key Long COVID and Parkinson's symptoms for targeted patient subgroups, with strong safety and biomarker results. FDA meetings for phase III trial designs are expected by year-end, and management is prioritizing non-dilutive funding and strategic partnerships.
BioVie Transcript: Study result
ADDRESS-LC phase II results show bezisterim significantly improves fatigue, malaise, and cognition in Long COVID patients with high baseline symptoms, with a strong safety profile and 78% responder rate. Experts recommend advancing to phase III and pursuing breakthrough designation.
BioVie Press release: Study result
BioVie issued a press release on September 15, 2026, disclosing material business information to investors.
BioVie Slides: Study result
BioVie has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
BioVie announces topline results from ADDRESS-LC trial
BioVie (BIVI) announced topline results from the company’s Phase 2 ADDRESS-LC trial evaluating its investigational drug candidate bezisterim, an oral drug that crosses the blood-brain barrier and is b...
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise
BioVie Slides: Corporate presentation
BioVie has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)
BioVie Announces Update to Parkinson's Phase 3 Development Program
Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease Company Corresponded with the FDA on an ...
BioVie completes treatment phase of ADDRESS-LC trial
BioVie (BIVI) announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed. The Phase…
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodeg...
BioVie Registration statement: Registration filing
BioVie filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
BioVie Annual report: Q4 2026
BioVie has published its Q4 2026 annual report on August 13, 2026.
BioVie Transcript: Study result
The SUNRISE-PD phase II trial of bezisterim in early Parkinson's showed significant improvements in both motor and non-motor symptoms, especially in patients with higher baseline inflammation. Biomarker data suggest slowed neurodegeneration, and the drug was well-tolerated, supporting a phase III trial with an enrichment strategy.
BioVie Slides: Study result
BioVie has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
BioVie Press release: Study result
BioVie issued a press release on August 12, 2026, disclosing material business information to investors.
BioVie says Phase 2 SUNRISE-PD trial of bezisterim met primary endpoint
BioVie (BIVI) announced results from the company’s Phase 2 SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease. The trial successfully met prespecified endpoin...
BioVie Registration statement: Registration filing
BioVie filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease
Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS 1 Parts I, II, and III, as well ...